Recent Updates
Recently added Catalysts
CV Positive Sentiment

CapsoVision to Release Third Quarter 2026 Financial Results on November 12, 2026

Key Takeaway: CapsoVision, a medical technology company, will announce its third quarter 2026 financial results on November 12, 2026. A conference call will follow to discuss the results and provide updates. The company focuses on advanced imaging and AI-enabled solutions for gastrointestinal diseases.

Market Sentiment Analysis

POSITIVE FACTORS

  • CapsoVision is advancing imaging technology for gastrointestinal diseases.
  • The company is set to release Q3 2026 financial results soon.
  • CapsoVision's products are designed to enhance non-invasive diagnostics.

Full Press Release Details

SARATOGA, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today announced that the Company will release third quarter 2026 financial results on Thursday, November 12, 2026, after the close of market. CapsoVision will host a corresponding conference call and a live webcast at 1:30 pm PT / 4:30 pm ET on the same day to discuss the results and provide a corporate update.
Investors interested in listening to the conference call may do so by dialing (800) 715-9871 or (646) 307-1963 and referencing conference ID 2841803. The live and archived webcast of the conference call can be found on the Events page in the Investor Relations section of CapsoVision’s website.

About CapsoVision

CapsoVision is a commercial-stage medical technology company focused on developing advanced imaging and AI-enabled solutions to transform the detection and screening of gastrointestinal diseases. Its flagship product, CapsoCam Plus®, is a wire-free, panoramic capsule endoscope that enables high-resolution visualization of the small bowel and supports cloud-based or direct capsule video review. The Company’s next pipeline product, CapsoCam Colon™ with enhanced AI, is designed to enable non-invasive colon imaging and polyp detection. With a proprietary platform targeted to expand across multiple GI indications, including esophageal and pancreatic disorders, CapsoVision is advancing a new era in capsule-based diagnostics. For more information on CapsoVision, please visit www.capsovision.com.

Investor Relations Contact Leigh Salvo New Street Investor Relations Investors@CapsoVision.com

Frequently Asked Questions

When will CapsoVision release its Q3 2026 results?

CapsoVision will release its Q3 2026 financial results on November 12, 2026.

What time is the CapsoVision conference call?

The conference call is scheduled for 1:30 pm PT / 4:30 pm ET.

How can investors join the conference call?

Investors can join by calling (800) 715-9871 or (646) 307-1963.

What is CapsoVision's flagship product?

CapsoVision's flagship product is the CapsoCam Plus®, a wire-free capsule endoscope.

Last updated: Oct 29, 2026